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Lung Metastasis Postradioembolization of
Hepatocellular Carcinoma With Tumor in Vein
Harit Kapoor, MBBS1, Sreeja Sanampudi, MD1, Joseph Owen, MD1, and Driss Raissi, MD1
1Department of Radiology, University of Kentucky Chandler Medical Center, Lexington, KY
ABSTRACT
Transarterial radioembolization (TARE) is one of the few treatment options available for infiltrative hepatocellular carcinoma with
tumor in vein. This is backed by the published data showing marginally favorable toxicity profile compared with other locoregional
and systemic therapies. Although lung shunt fraction studies are performed to prevent radiation injury to the lungs, TARE-induced
embolization/metastasis to the lungs has not been reported before. We report an intriguing case of new lung metastases within 1
month after TARE for infiltrative hepatocellular carcinomawith a tumor in the vein, with only a slightly elevated but acceptable lung
shunt fraction. This report brings to light the possibility of such a complication and argues for improved preprocedural assessment of
a tumor in vein burden and embolization potential.
INTRODUCTION
Infiltrative hepatocellular carcinoma (IHCC) is a subtype of advanced HCC that carries a very poor prognosis, especially when
associated with tumor in vein (TIV). In these patients, treatment options are limited.1 Locoregional therapies such as transarterial
radioembolization (TARE) with or without chemotherapy are performed in the liver-limited disease to downstage. TARE delivers
hepatic-selective brachytherapy, relying on the preferential arterial perfusion of the tumor. TARE has been shown to offer some
survival benefit but more importantly a milder toxicity profile compared with other therapies for IHCC-TIV.2,3 We present an
intriguing case of new lung metastases within 1 month after radioembolization of an IHCC-TIV.
CASE REPORT
A 56-year-old man with hepatitis C-related cirrhosis presented with new right upper abdominal pain. Other comorbidities included
hypertension, coronary artery disease status post bypass grafting, and epilepsy. He denied gastroenterology follow-up after the
diagnosis of cirrhosis 5 years ago. History of present illness revealed unintentional weight loss of 50 pounds and dark colored urine
worsening over the past year. Mild icterus and right upper quadrant tenderness were elicited on physical examination. Laboratory
workup revealed an hemoglobin of 13.5 g/dL, platelets of 205 k/uL, creatinine of 0.6 mg/dL, aspartate aminotransferase of 198 U/L,
alanine aminotransferase of 41 U/L, alkaline phosphatase level of 119 IU/L, international normalized ratio of 1.2, serum sodium of
127 mmol/L, bilirubin of 2.1 mg/dL, and alpha-feto-protein (AFP) level of 354,260 ng/mL. Specific disease scores were calculated to
be Child-Pugh Class B and Model for End-Stage Liver Disease—Sodium of 21. Imaging showed an infiltrative necrotic 123 10-cm
mass within posterior segments of the right liver (VI and VIII) along with the thrombosis of the right posterior portal vein, reported
as Liver Imaging Reporting and Data System—TIV (Figure 1). A complete diagnosis of unresectable Stage IV-B (T3bN1M0)
hepatocellular carcinoma was made after tumor board review. Interventional radiology was consulted for TARE. Review of pre-
procedural imaging revealed unremarkable arterial anatomy. Three weeks later, the patient underwent arterial mapping with
Technetium-99m macroaggregated albumin (Tc-99m MAA; 4.15 mCi) via standard right femoral artery access and right hepatic
superselection. Postmapping liver imaging with single-photon emission computed tomography (SPECT-CT) revealed the expected
tracer distribution and an acceptable but borderline high-lung shunt fraction (LSF) of 11% (Figure 2). After another 5-week interval,
133.5mCi dose of Y-90 TheraSphere (MDS Nordion, Ottawa, ON, Canada) was administered to targeted segments.
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Tracer localization was limited to tumor-containing hepatic
segments on postprocedure bremsstrahlung SPECT-CT. Un-
fortunately, the patient presented back to the emergency de-
partment 3 weeks post-TARE with severe abdominal pain.
Abdominal, thoracic, and pelvic contrast-enhanced CT dem-
onstrated necrosis within the index tumor (Figure 3) but with
new findings of multiple lung metastases which were not
present on the thoracic CT performed 53 days before Y-90
embolization (Figure 4). Laboratory test results revealed only
a modest drop in AFP. Prominent arterioportal shunting was
evident on a retrospective review of intraprocedural images
(Figure 5). The patient did not tolerate sorafenib therapy and
ultimately opted for home hospice.
DISCUSSION
We present a case of metastatic disease to the lungs within one
month after radioembolization of an infiltrative HCC with
branch portal vein thrombus. A significant limitation to this
report is the possibility of metastatic progression in the near 2-
month gap period between preoperative imaging and emboli-
zation, especially considering the aggressive tumor profile.
However, it would be irrational to dismiss the alternative pos-
sibility of iatrogenic metastatic facilitation.
Embolization with beta-emitter Y-90 is indicated in unre-
sectable HCC when (i) HCC is liver limited, (ii) expected
survival of at least 12 weeks with the Eastern Cooperative
Oncology Group (ECOG) performance status of, 2, and (iii)
acceptable hepatic functional status (lack of ascites, total bil-
irubin ,2 mg/dL, and albumin .3 mg/dL).4 Absolute con-
traindications to the procedure include a LSF . 20%
or a predicted single session lung dose estimation of. 30 Gy
on postmapping SPECT.4 Complications include procedure-
related vascular injury, postembolization syndrome, and
most importantly complications arising from nontarget
embolization.
Radiation pneumonitis can be a serious complication with
hepatopulmonary shunting being quite common in patients
with cirrhosis. In fact, patients who develop HCC and espe-
cially those with IHCC-TIV are more strongly associated with
such shunting.5 This very disease attributemakes itmandatory
to performpreproceduremapping to estimate LSF. In addition
to being a good predictor for complications such as radiation
pneumonitis, LSF has also been shown to be an independent
predictor of metastatic risk in HCC, with 2 times higher LSFs
in those with extrahepatic metastases.6 LSF is currently
Figure 1. Axial contrast-enhanced computed tomography images
before transarterial radioembolization showing a necrotic mass
(white star) and tumor in the veinwithin the right posterior portal vein
branch (white arrow).
Figure 2. Single-photon emission computed tomography imaging
after initial arterial mapping procedure.
Figure 3.Retrospective review of intraprocedural digital subtraction
angiographic acquisition showing prominent arterioportal shunting.
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performed by injecting Tc-99m MAA intra-arterially into the
liver as a test run before actual Y-90 administration. In most
centers, images are then obtained using a planar gamma
camera. The fraction of total counts reaching the lung (LSF)
are derived by calculating the geometric mean of counts
detected in themanually drawn region of interest over the lung
on both anterior and posterior planar views. LSF values are
known to become less reliable with time, especially beyond 4
hours because of biologic disintegration of MAA.7 LSF was
calculated with planar imaging at 45 minutes postinjection in
our case. Although SPECT-CT is performed at many centers,
for visual assessment of extrahepatic deposition, it is not
routinely used for LSF calculation. Given its poor anatomic
resolution and the inability of performing attenuation cor-
rection, planar imaging is prone to overestimation of shunt
fractionwhen comparedwith SPECT-CT.8 Ideally, LSF should
be less than 10%. Although dose adjustments can be per-
formed in patients with LSF ranging between 10% and 20%,
those with LSF exceeding 20% are excluded from treatment.9
Although our patient only had a borderline high LSF of 11%,
multiple other risk factors for metastatic progression were
present including a large tumor burden with macrovascular
invasion and very high AFP levels. To this point, Fleming et al
proposed a judicious way of pre-TARE patient selection by
inversely customizing the LSF cutoff based on anatomic tumor
bulk and aggressive features.5
An abscopal effect of radiation-induced augmentation of anti-
tumor immune response has been described in the literature.10
On the contrary, this case exhibits a “reverse” abscopal effect.
Figure 4. Representative lung window computed tomography images at comparable axial and sagittal planes, (A) before and (B) after
transarterial radioembolization showing the development of new multifocal rounded pulmonary metastasis (yellow circles).
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Our literature search for similar cases incidentally revealed
a growing body of evidence showing a trend for regional
(but not metastatic) tumor potentiation after other locore-
gional therapies including ablation and transarterial
chemoembolization.11–13 Tumor size, proximity to a sizeable
portal vein, infiltrative morphology, and lower age have been
linked to higher risk of such an occurrence.11 Multiple potential
mechanisms have been proposed: (i) iatrogenic arterioportal
shunt creation, (ii) induction of immune activation (high re-
gional hepatocyte growth factor which in turn can activate
downstream c-Met pathway leading to a greater vascular endo-
thelial growth factor synthesis) and, (iii) increased intratumor
pressure from associated edema causing rupture of the index
lesion and dissemination of viable tumor cells.11,12,14 In conclu-
sion, this report brings to light the possibility of metastatic po-
tentiation after TARE in patients with IHCC-TIV and argues for
improved preprocedural assessment of TIV burden and
thoughtful consideration of adjunctive biochemical markers,
especially when deciding for TARE candidacy in patients with
borderline elevated LSF values.
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Figure 5. Axial contrast-enhanced computed tomography images
taken 53 days after transarterial radioembolization showing the
necrosis of the index tumor (black star).
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